This review aims to evaluate critically the current advances in the interpretation of tau-based biomarkers and their use to provide insights into the onset and progression of Alzheimer’s disease, whilst highlighting important future directions for the field. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.